蓝光光生物调节（PBM）最近在减少癌细胞增殖和诱导癌细胞死亡方面引起了广泛关注。骨肉瘤（OS）主要发生于儿童和青少年，耐药性和保肢的局限性使得迫切需要开发和确定新的辅助治疗策略。在这项工作中，我们试图研究蓝光PBM对人OS MG63细胞的抗癌作用和生物学机制。各种蓝光参数对 MG63 细胞的影响表明，抑制细胞增殖和细胞迁移，诱导细胞凋亡，并使用 CCK、LDH、伤口愈合测定和 Hoechst 染色等多种测定法进行实验评估。同时，在高剂量蓝光 PBM 下，MG63 细胞中 ROS 水平增加，PI3K 和 AKT 表达受到抑制。同时，SOCS3是一种主要的诱导型抗肿瘤分子，我们还发现蓝光LED显着促进了其表达。因此，本研究提出蓝光 PBM 可能成为未来 OS 临床治疗中一种有希望的治疗方法。版权所有 © 2023 Elsevier B.V. 保留所有权利。

Blue light photobiomodulation (PBM) has attracted great attention in diminishing proliferation and inducing death of cancer cells recently. Osteosarcoma (OS) primarily occurring in children and adolescents, the limitations of drug resistance and limb salvage make it urgent to develop and identify new adjuvant therapeutic strategies. In this work, we attempted to research the anticancer effects and biological mechanisms of blue light PBM in human OS MG63 cells. The effects of various blue light parameters on MG63 cells indicated that suppressed cell proliferation and cell migration, induced cell apoptosis which are experimentally assessed using multiple assays including CCK, LDH, wound healing assay and Hoechst staining. Concurrently, the increases of ROS level and the inhibition of PI3K and AKT expression were identified under high-dose blue light PBM in MG63 cells. Meanwhile, SOCS3 is a major inducible anti-tumor molecule, we also found that blue light LED substantially promoted its expression. Thus, this study proposed that bule light PBM may be a hopeful therapeutic approach in OS clinical treatment in the future.Copyright © 2023 Elsevier B.V. All rights reserved.